Beijing Pro-med Technology Co., Ltd. was established in 2013 in Changping District of Beijing Zhongguancun Science And Technology Park, it is a high-tech enterprise focusing on the service of maternal and child health in the field of in vitro diagnosis, mainly engaged in the research and development, production and sales of equipment and reagents related to POCT, clotting and molecular diagnosis platforms.

In 2017, the company successfully obtained A round of financing, and invested in the establishment of A wholly-owned subsidiary, Jiangsu Aoya biotechnology co., ltd. in China pharmaceutical city, to comprehensively upgrade the research and development center and production base. At present, the company has 8,000 square meters of production and development site, 1,000 square meters of GMP workshop, more than 30 core patents authorized, more than 80 product registration certificates, the products have been sold to more than 5,000 medical institutions in more than 30 provinces.

The company focuses on maternal and child health, the products cover POCT, clotting and molecular diagnosis. POCT product line mainly includes more than 60 detection reagents of health elements, pediatric infection, cardiovascular and cerebrovascular diseases, stomach health, and women's health. And gradually formed the advantage characteristic project, consist of heart failure combined detection reagent (sST2/ Nt-proBNP), combination of inflammatory infection detection reagents (SAA/CRP), anti mullerian hormone (AMH), ferritin, vitamin D, combined of pepsinogen detection reagent (PG Ⅰ/PGⅡ). The company insists on reagents/testing platform self-research and self-production, and constantly launches more POCT testing products with market competitiveness based on its own PMDT testing platform. The company's clotting product line is represented by the CWPS thromboelastogram, which can provide a variety of detection reagents such as ordinary cup, heparinase cup, platelet aggregation, rapid coagulation and quality control products for different clinical situations. In the form of the combination of images and indicators, the individual, continuous and visual global judgment of the clinical outcome/coagulation situation is realized. The company's molecular diagnostic product line relies on the company's strong research and development ability and rich experience in the detection of inflammatory infection, a series of molecular microfluidic detection reagents represented by the nine joint examination of respiratory pathogens and the twelve joint examination of respiratory pathogens were creatively developed. The company's three IVD product lines are dedicated to providing convenient, visual and accurate medical testing services, it can effectively relieve the pressure of terminal test, assist clinical comprehensive diagnosis, and improve the efficiency of medical institutions.

The company will always adhere to the " Comprehensive but excellent, for the health of women and children " business philosophy, with the mission of "maternal and child health", relying on high and new technology, relying on comprehensive inspection products, top technical team, first-class round-the-clock service, good faith and professional enterprise style, perfect immediate diagnosis plan, determined to create a core competitive in vitro diagnosis brand, through continuous efforts to promote the development of the medical cause, improve the construction of a healthy China, to achieve all-round and full cycle to ensure the health of the people's contribution.

Login by:
leave a message
back to the top